


PHARMACEUTICAL 2023



Protagonist Therapeutics Inc Rank 125 of 446





PHARMACEUTICAL 2023



Protagonist Therapeutics Inc Rank 125 of 446

The relative strengths and weaknesses of Protagonist Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Protagonist Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Protagonist Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 174%, being 131% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	243,077
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,179
Liabilities, Non-Current	1,141
Other Assets	3,286
Other Compr. Net Income	-60
Other Expenses	0
Other Liabilities	0
Other Net Income	3,980
Other Revenues	26,581
Property and Equipment	1,565
Research and Development	126,215
Selling, General and Administrative Expense	31,739

Output Variable	Value in 1000 USD
Assets	247,928
Liabilities	32,320
Expenses	157,954
Revenues	26,581
Stockholders Equity	215,608
Net Income	-127,393
Comprehensive Net Income	-127,423
Economic Capital Ratio	174%

